|
|
|
|
|
by Ulrich2
1962 days ago
|
|
Please stop spreading lies. The paper is only about "The effectiveness of the first dose of BNT162 ..." 50% efficacy after the first dose is exactly the number that BioNTech reported in its Phase3 trial. So nothing unusual here. That is why the 2nd booster shot is needed to get to 95%. |
|
The graphs, both in Pfizer’s original report and in this paper, show that past about two weeks, there is almost no change. Please look at the Pfizer graphs and tell me where the great advance is from 50% to 90%
Also, if yo actually read the Pfizer report, you’ll notice the 95% is for mild disease - a totally uninteresting result. For severe disease, it is 75% with a CI spanning the whole 0-100% range.